Dr. Meyer is an academically trained pulmonologist and critical care specialist and a regulatory science expert by vocation. He is currently a Principal of Drug and Biological Products at Greenleaf Health Inc., a regulatory consulting firm in Washington DC. He is also an Associate Professor of Public Health Sciences at UVA, a position he held as a full-time faculty from 2013-2017.
Prior to joining the UVA faculty, Dr. Meyer was Vice President and head, Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories (MRL) where he was responsible for all regulatory strategy and operations, global regulatory policy and intelligence, and global product safety and pharmacovigilance. At MRL, Dr. Meyer served on Development Review Committee for all clinical stages, the Safety Review Committee and chaired the Development Policy Committee. Dr. Meyer chaired the Regulatory Affairs Coordinating Committee for Pharmaceutical Research and Manufacturers of America (PhRMA) from 2012-13 and served as a key PhRMA negotiator on PDUFA V. Prior to Merck, Dr. Meyer was at the FDA for 13 years. His last position at the FDA was as the Director for the Office of Drug Evaluation II (ODEII) within CDER, with responsibilities for pulmonary and allergy, metabolic and endocrine, and analgesics, anesthetics and rheumatologic drug products from 2002-2007. Besides his formal role, Dr. Meyer was involved in several CDER initiatives, amongst them chairing the development of the Pre-Market Risk Assessment guidance. Additionally, he participated with the FDA negotiation team in the PDUFA III and IV.
Dr. Meyer serves as an expert to the Medical Aerosols Technical Options Committee of the United Nations. Besides his Trustee role with USP, Dr. Meyer is on the Board of Directors of Correvio Pharma, Chimerix and Translate BIO.